Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Anti-Cancer Drugs

• Publication date

  2017-11-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1097/CAD.0000000000000545PMID 28857767
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.

  2016cited by this paper
• Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression.

  2016cited by this paper
• Efficacy of different monotherapies in second-line treatment for small cell lung cancer: a meta-analysis of randomized controlled trials.

  2015cited by this paper
• Macrophages of M1 phenotype have properties that influence lung cancer cell progression

  2015cited by this paper
• Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High SLFN11 Expression

  2015cited by this paper
• Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer.

  2014cited by this paper
• Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion.

  2014cited by this paper
• Treatment of small cell lung cancer.

  2014cited by this paper
• 261 Lesion characterization with ferumoxytol MRI in patients with advanced solid tumors and correlation with treatment response to MM-398, nanoliposomal irinotecan (nal-IRI)

  2014cited by this paper
• Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2013cited by this paper
• Combination of HDAC and topoisomerase inhibitors in small cell lung cancer

  2012cited by this paper
• Investigation of intravenous delivery of nanoliposomal topotecan for activity against orthotopic glioblastoma xenografts.

  2011cited by this paper
• Irinotecan as a second-line monotherapy for small cell lung cancer.

  2011cited by this paper
• Small Cell Lung Cancer: Are We Making Progress?

  2010cited by this paper
• A Meta-Analysis of Randomized Controlled Trials Comparing Irinotecan/Platinum with Etoposide/Platinum in Patients with Previously Untreated Extensive-Stage Small Cell Lung Cancer

  2010cited by this paper
• Development of a highly stable and targetable nanoliposomal formulation of topotecan.

  2010cited by this paper
• A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease.

  2010cited by this paper
• The Critical Role of Neutral Cholesterol Ester Hydrolase 1 in Cholesterol Removal From Human Macrophages

  2010cited by this paper
• A multicenter randomized phase II study of the irinotecan/gemcitabine doublet versus irinotecan monotherapy in previously treated patients with extensive stage small-cell lung cancer.

  2009cited by this paper
• Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.

  2009cited by this paper
• Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial.

  2008cited by this paper
• Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy.

  2006cited by this paper
• In‐vitro cytotoxicity, in‐vivo biodistribution and anti‐tumour effect of PEGylated liposomal topotecan

  2005cited by this paper
• Treatment of small cell lung cancer.

  2004cited by this paper
• Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice

  2004cited by this paper
• Phase II study of pegylated liposomal doxorubicin HCl (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer.

  2003cited by this paper
• Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan.

  2002cited by this paper
• Schedule-dependent activity of topotecan in OVCAR-3 ovarian carcinoma xenograft: pharmacokinetic and pharmacodynamic evaluation.

  2001cited by this paper
• Phase II study of pegylated liposomal doxorubicin: inactive in recurrent small-cell lung cancer. A Hellenic Cooperative Oncology Group Study.

  2000cited by this paper
• Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models.

  2000cited by this paper
• A high number of tumor-infiltrating lymphocytes are associated with a small tumor size, low tumor stage, and a favorable prognosis in operated small cell lung carcinoma.

  2000cited by this paper
• Determinants of CPT-11 and SN-38 activities in human lung cancer cells.

  1998cited by this paper
• Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan.

  1998cited by this paper
• Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development.

  1997cited by this paper
• Schedule‐dependent Efficacy of Camptothecins in Models of Human Cancer a

  1996cited by this paper
• Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks

  1995cited by this paper
• CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer.

  1992cited by this paper

• The application development of nanoparticle-based drug delivery systems in combating drug resistance of lung cancer

  2026cites this paper
• Natural Products in Cancer Prevention and Therapy: Current Challenges and Future Directions

  2026cites this paper
• Nanoliposomal Irinotecan With Fluorouracil and Folinic Acid in Older Versus Younger Patients With Unresectable Pancreatic Cancer: The Multicenter NAPOLEON-2 Study.

  2025cites this paper
• Conditions for effective use of liposomal irinotecan with fluorouracil and leucovorin in unresectable pancreatic cancer after FOLFIRINOX treatment

  2025cites this paper
• Minocycline and photodynamic priming significantly improve chemotherapy efficacy in heterotypic spheroids of pancreatic ductal adenocarcinoma.

  2024cites this paper
• Survival predictors in patients with pancreatic cancer on liposomal irinotecan plus fluorouracil/leucovorin: a multicenter observational study

  2024cites this paper
• Second-line and third-line therapy with nanoliposomal irinotecan (nal-IRI) in pancreatic cancer: a single-center experience and review of literature

  2023cites this paper
• Topoisomerase I inhibitors: Challenges, progress and the road ahead.

  2022cites this paper
• A novel NCI‐H69V small cell lung cancer functional mini‐tumor model for future treatment screening applications

  2022influential citation
• Liposomal irinotecan (Onivyde): Exemplifying the benefits of nanotherapeutic drugs

  2022cites this paper
• Augmenting Experimental Gastric Cancer Activity of Irinotecan through Liposomal Formulation and Antiangiogenic Combination Therapy

  2022cites this paper
• Advances in biology and novel treatments of SCLC: The four-color problem in uncharted territory.

  2022cites this paper
• Topoisomerase 1 inhibition modulates pyroptosis to improve recovery after spinal cord injury

  2022cites this paper
• Nanomedicine for targeting the lung cancer cells by interpreting the signaling pathways

  2022cites this paper
• The Development of Investigator-Initiated Clinical Trials in Surgical Oncology.

  2022cites this paper
• A Multicenter Phase 1 Trial Evaluating Nanoliposomal Irinotecan for Heated Intraperitoneal Chemotherapy Combined with Cytoreductive Surgery for Patients with Peritoneal Surface Disease

  2022cites this paper
• Drug Stability and Minimized Acid-/Drug-Catalyzed Phospholipid Degradation in Liposomal Irinotecan.

  2022cites this paper
• Nanoliposomal irinotecan in combination with leucovorin and 5-fluorouracil in advanced biliary tract cancers

  2021cites this paper
• Novel Cytotoxic Chemotherapies in Small Cell Lung Carcinoma

  2021cites this paper
• A brain proteomic signature of incipient Alzheimer’s disease in young APOE ε4 carriers identifies novel drug targets

  2021cites this paper
• Nanoparticles from Gantrez-based conjugates for the oral delivery of camptothecin

  2021cites this paper
• Current Strategies for Extensive Stage Small Cell Lung Cancer Beyond First-line Therapy.

  2021cites this paper
• Applications and strategies in nanodiagnosis and nanotherapy in lung cancer.

  2020cites this paper
• Recent Advancements in Liposome-Targeting Strategies for the Treatment of Gliomas: A Systematic Review.

  2020cites this paper
• Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer

  2019cites this paper
• Topoisomerase inhibitors: pharmacology and emerging nanoscale delivery systems.

  2019cites this paper
• Potent Antitumor Activity of Liposomal Irinotecan in an Organoid- and CRISPR-Cas9-Based Murine Model of Gallbladder Cancer

  2019cites this paper
• Irinotecan: 25 years of cancer treatment.

  2019cites this paper
• Liposome-Based Drug Delivery for Lung Cancer

  2019cites this paper
• Preparation and Evaluation of Irinotecan Poly(Lactic-co-Glycolic Acid) Nanoparticles for Enhanced Anti-tumor Therapy

  2019cites this paper
• Simultaneous quantification of Gemcitabine and Irinotecan hydrochloride in rat plasma by using high performance liquid chromatography‐diode array detector

  2018cites this paper